320 WEST 37TH STREET, NEW YORK, NY
Immunovant, Inc. Annual Meeting of Stockholders Held on September 2, 2026
Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
Annual Report to Security Holders
Earnings Release
Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
Immunovant, Inc. Completes $550 Million Underwritten Offering
Other Events
Michael Geffner, M.D. Departs as Chief Medical Officer of Immunovant
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Notice of Exempt Offering of Securities
S-3ASR
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Free Writing Prospectus
Submission Upload
Correspondence